Company Information

MARKSANS PHARMA LTD.

NSE : MARKSANSBSE : 524404ISIN CODE : INE750C01026Industry : Pharmaceuticals & DrugsHouse : Private
BSE172.205.3 (+3.18 %)
PREV CLOSE ( ) 166.90
OPEN PRICE ( ) 166.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 182447
TODAY'S LOW / HIGH ( )166.25 173.85
52 WK LOW / HIGH ( )70.2 185.4
NSE172.155 (+2.99 %)
PREV CLOSE( ) 167.15
OPEN PRICE ( ) 167.50
BID PRICE (QTY) 172.15 (550)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2110794
TODAY'S LOW / HIGH( ) 166.15 173.80
52 WK LOW / HIGH ( )70.55 185.5
ChairmanMark Saldanha
Managing DirectorMark Saldanha
Company SecretaryHarshavardhan Panigrahi
Non Executive Independent DirectorSeetharama Raju Buddharaju
Digant Mahesh Parikh
Abhinna Sundar Mohanty
Shailaja Vardhan
Whole Time DirectorSandra Saldanha
Varddhman Vikramaditya Jain
Non Independent & Non Executive DirectorSunny Sharma
Incorporation Year : 1992

Registered Office :

Address : 11th Floor, " Grandeur " Opp. Gundecha Symphony,Veera Desai Extension Road,Oshiwara, Andheri (W) Mumbai,
Maharashtra-400053 .

Phone : 022- 40012000

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.